Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Free Cash Flow: 2017-2024

Historic Free Cash Flow for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to -$521.7 million.

  • BridgeBio Pharma's Free Cash Flow rose 39.10% to -$110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$585.9 million, marking a year-over-year decrease of 29.76%. This contributed to the annual value of -$521.7 million for FY2024, which is 1.39% up from last year.
  • Per BridgeBio Pharma's latest filing, its Free Cash Flow stood at -$521.7 million for FY2024, which was up 1.39% from -$529.0 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Free Cash Flow peaked at -$407.2 million during FY2020, and registered a low of -$529.0 million during FY2023.
  • Over the past 3 years, BridgeBio Pharma's median Free Cash Flow value was -$521.7 million (recorded in 2024), while the average stood at -$491.7 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first slumped by 58.94% in 2020, then increased by 16.99% in 2022.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Free Cash Flow stood at -$407.2 million in 2020, then decreased by 25.53% to -$511.2 million in 2021, then climbed by 16.99% to -$424.3 million in 2022, then dropped by 24.68% to -$529.0 million in 2023, then increased by 1.39% to -$521.7 million in 2024.